581P - A biomarker combination indicating resistance to FOLFOX plus bevacizumab in metastatic colorectal cancer: Results of phase I of the PERMAD trial
| Autor: | Seufferlein, T., Ettrich, T.J., Stein, A., Arnold, D., Prager, G., Kasper, S., Niedermeier, M., Mueller, L., Kubicka, S., König, A.-O., Büchner-Steudel, P., Wille, K., Kestler, A., Hann, A., Perkhofer, L., Berger, A.W., Lausser, L., Kestler, H. |
|---|---|
| Zdroj: | In Annals of Oncology October 2019 30 Supplement 5:v219-v220 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|